These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

176 related articles for article (PubMed ID: 36585178)

  • 21. FDG PET/CT in differentiated thyroid cancer patients with low thyroglobulin levels.
    Lebbink CA; de Vries LH; Borel Rinkes IHM; Braat AJAT; van Leeuwaarde RS; Lodewijk L; van Treijen MJC; Vriens MR; Valk GD; van Santen HM; de Keizer B
    Eur J Endocrinol; 2022 May; 187(1):101-110. PubMed ID: 35521710
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Relationship between circulating anti-thyroglobulin antibodies (TgAb) and tumor metabolism in patients with differentiated thyroid cancer (DTC): prognostic implications.
    Morbelli S; Ferrarazzo G; Pomposelli E; Pupo F; Pesce G; Calamia I; Fiz F; Clapasson A; Bauckneht M; Minuto M; Sambuceti G; Giusti M; Bagnasco M
    J Endocrinol Invest; 2017 Apr; 40(4):417-424. PubMed ID: 27844413
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [18F]-FDG-PET/CT Correlates With the Response of Radiorefractory Thyroid Cancer to Lenvatinib and Patient Survival.
    Valerio L; Guidoccio F; Giani C; Tardelli E; Puccini G; Puleo L; Minaldi E; Boni G; Elisei R; Volterrani D
    J Clin Endocrinol Metab; 2021 Jul; 106(8):2355-2366. PubMed ID: 33901285
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prognostic Value of FDG-PET/CT Metabolic Parameters in Metastatic Radioiodine-Refractory Differentiated Thyroid Cancer.
    Manohar PM; Beesley LJ; Bellile EL; Worden FP; Avram AM
    Clin Nucl Med; 2018 Sep; 43(9):641-647. PubMed ID: 30015659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. The role of FDG-PET in localization of recurrent lesions of differentiated thyroid cancer (DTC) in patients with asymptomatic hyperthyroglobulinemia in a real clinical practice.
    Kukulska A; Krajewska J; Kołosza Z; Paliczka-Cies Lik E; Puch Z; Gubała E; Król A; Kalemba M; Kropin Ska A; Jarząb B
    Eur J Endocrinol; 2016 Nov; 175(5):379-85. PubMed ID: 27511823
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Could [18]F-fluorodeoxyglucose PET/CT change the therapeutic management of stage IV thyroid cancer with positive (131)I whole body scan?
    Piccardo A; Foppiani L; Morbelli S; Bianchi P; Barbera F; Biscaldi E; Altrinetti V; Villavecchia G; Cabria M
    Q J Nucl Med Mol Imaging; 2011 Feb; 55(1):57-65. PubMed ID: 21285923
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Role of Thyroglobulin Doubling Time in Differentiated Thyroid Cancer and Its Relationship with Demographic-Histopathologic Risk Factors and
    Araz M; Soydal Ç; Özkan E; Akkuş P; Nak D; Küçük NÖ; Kır KM
    Cancer Biother Radiopharm; 2021 Jun; 36(5):425-432. PubMed ID: 32379488
    [No Abstract]   [Full Text] [Related]  

  • 28. Does recombinant human thyrotropin-stimulated positron emission tomography with [18F]fluoro-2-deoxy-D-glucose improve detection of recurrence of well-differentiated thyroid carcinoma in patients with low serum thyroglobulin?
    Vera P; Kuhn-Lansoy C; Edet-Sanson A; Hapdey S; Modzelewski R; Hitzel A; d'Anjou J; Basuyau JP
    Thyroid; 2010 Jan; 20(1):15-23. PubMed ID: 20017617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Effectiveness of [(124)I]-PET/CT and [(18)F]-FDG-PET/CT for localizing recurrence in patients with differentiated thyroid carcinoma.
    Lee J; Nah KY; Kim RM; Oh YJ; An YS; Yoon JK; An GI; Choi TH; Cheon GJ; Soh EY; Chung WY
    J Korean Med Sci; 2012 Sep; 27(9):1019-26. PubMed ID: 22969247
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diagnostic accuracy of (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in differentiated thyroid cancer patients with elevated thyroglobulin and negative (131)I whole body scan: evaluation by thyroglobulin level.
    Na SJ; Yoo IeR; O JH; Lin C; Lin Q; Kim SH; Chung SK
    Ann Nucl Med; 2012 Jan; 26(1):26-34. PubMed ID: 21971605
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pre-Ablation rhTSH-Stimulated F-18 FDG PET/CT Changes Patient Management in Increased-Risk Thyroid Cancer.
    Rendl G; Rettenbacher L; Schweighofer-Zwink G; Hehenwarter L; Pirich C
    Horm Metab Res; 2020 Mar; 52(3):158-167. PubMed ID: 32215887
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Imaging in endocrinology: 2-[18F]-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in differentiated thyroid carcinoma: clinical indications and controversies in diagnosis and follow-up.
    Salvatori M; Biondi B; Rufini V
    Eur J Endocrinol; 2015 Sep; 173(3):R115-30. PubMed ID: 25947140
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [(68)Ga]DOTATATE PET/MRI and [(18)F]FDG PET/CT are complementary and superior to diffusion-weighted MR imaging for radioactive-iodine-refractory differentiated thyroid cancer.
    Vrachimis A; Stegger L; Wenning C; Noto B; Burg MC; Konnert JR; Allkemper T; Heindel W; Riemann B; Schäfers M; Weckesser M
    Eur J Nucl Med Mol Imaging; 2016 Sep; 43(10):1765-72. PubMed ID: 27059853
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Prognostic significance of FDG PET/CT on the follow-up of patients of differentiated thyroid carcinoma with negative 131I whole-body scan and elevated thyroglobulin levels: correlation with clinical and histopathologic characteristics and long-term follow-up data.
    Vural GU; Akkas BE; Ercakmak N; Basu S; Alavi A
    Clin Nucl Med; 2012 Oct; 37(10):953-9. PubMed ID: 22899202
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Combined metabolic and morphologic imaging in thyroid carcinoma patients with elevated serum thyroglobulin and negative cervical ultrasonography: role of 124I-PET/CT and FDG-PET.
    Freudenberg LS; Antoch G; Frilling A; Jentzen W; Rosenbaum SJ; Kühl H; Bockisch A; Görges R
    Eur J Nucl Med Mol Imaging; 2008 May; 35(5):950-7. PubMed ID: 18193222
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron Emission Tomography/Computed Tomography in Thyroid Cancer: An Updated Review.
    Chandekar KR; Satapathy S; Bal C
    PET Clin; 2024 Apr; 19(2):131-145. PubMed ID: 38212213
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Can (18)F-FDG-PET/CT be generally recommended in patients with differentiated thyroid carcinoma and elevated thyroglobulin levels but negative I-131 whole body scan?
    Bannas P; Derlin T; Groth M; Apostolova I; Adam G; Mester J; Klutmann S
    Ann Nucl Med; 2012 Jan; 26(1):77-85. PubMed ID: 22006540
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The usefulness of fluorine-18 fluorodeoxyglucose PET in the detection of recurrence in patients with differentiated thyroid cancer with elevated thyroglobulin and negative radioiodine whole-body scan.
    Stangierski A; Kaznowski J; Wolinski K; Jodlowska E; Michaliszyn P; Kubiak K; Czepczynski R; Ruchala M
    Nucl Med Commun; 2016 Sep; 37(9):935-8. PubMed ID: 27383190
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Prognostic implication of fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography in patients with recurrent papillary thyroid cancer.
    Kang JH; Jung DW; Pak KJ; Kim IJ; Kim HJ; Cho JK; Shin SC; Wang SG; Lee BJ
    Head Neck; 2018 Jan; 40(1):94-102. PubMed ID: 29130586
    [TBL] [Abstract][Full Text] [Related]  

  • 40. 68Ga-DOTATOC PET/CT in Patients with Iodine- and 18F-FDG-Negative Differentiated Thyroid Carcinoma and Elevated Serum Thyroglobulin.
    Binse I; Poeppel TD; Ruhlmann M; Ezziddin S; Görges R; Sabet A; Beiderwellen K; Bockisch A; Rosenbaum-Krumme SJ
    J Nucl Med; 2016 Oct; 57(10):1512-1517. PubMed ID: 27033897
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.